BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.

Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.

[1]  C. Coltman,et al.  Comparison of adriamycin‐containing chemotherapy (MOP‐BAP) with MOPP‐bleomycin in the management of advanced Hodgkin‐s disease a southwest oncology group study , 1983, Cancer.

[2]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[3]  T. Pajak,et al.  Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. , 1982, Cancer treatment reports.

[4]  A. Santoro,et al.  Alternating drug combinations in the treatment of advanced Hodgkin's disease. , 1982, The New England journal of medicine.

[5]  C. Bloomfield,et al.  Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. , 1982, Cancer treatment reports.

[6]  Coltman Ca,et al.  Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. , 1982 .

[7]  R. Comis,et al.  The pulmonary toxicity of antineoplastic agents. , 1982, Seminars in oncology.

[8]  H. Feiner,et al.  Nephrotoxicity of nitrosoureas , 1981, Cancer.

[9]  P. Wiernik,et al.  Treatment of advanced untreated Hodgkin's disease with SCAB—an alternative to MOPP , 1981, Cancer.

[10]  T. Pajak,et al.  A new effective four‐drug combination of CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea) (NSC‐79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease , 1980, Cancer.

[11]  B. Clarkson,et al.  The eight‐drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow‐up report , 1980, Cancer.

[12]  C. Coltman.  Chemotherapy of advanced Hodgkin's disease. , 1980, Seminars in oncology.

[13]  V. Devita,et al.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. , 1980, Annals of internal medicine.

[14]  S. Besuschio,et al.  Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) V.S. CVPP PLUS CCNU (CCVPP) in Hodgkin's disease , 1979, Cancer.

[15]  A. Bartolucci,et al.  BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease , 1978, Cancer.

[16]  T. Lister,et al.  MVPP chemotherapy regimen for advanced Hodgkin's disease , 1978, British medical journal.

[17]  D. T. Harrison,et al.  Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone. , 1977, Cancer treatment reports.

[18]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[19]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[20]  J. Bennett,et al.  Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group. , 1976, Cancer treatment reports.

[21]  R. Dorfman,et al.  A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (mopp) vs. nitrogen mustard in advanced hodgkin's disease , 1975, Cancer.

[22]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[23]  D. Nixon,et al.  Combination chemotherapy of Hodgkin's disease , 1974, Cancer.

[24]  O. Glidewell,et al.  Multiple chemotherapeutic agents for Hodgkin disease. Comparison of three routines: a cooperative study by acute leukemia group B. , 1973, JAMA.

[25]  J. Durant,et al.  Development of four‐drug bcnu combination chemotherapy regimens. (Writing committee for southeastern cancer study group) , 1973, Cancer.

[26]  J. Bull,et al.  MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients , 1973, Cancer.

[27]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[28]  V. Devita,et al.  Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. , 1971, The New England journal of medicine.

[29]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.

[30]  H. Lessner,et al.  BCNU (1,3), BIS(B‐chloroethyl)‐1‐nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia , 1968, Cancer.

[31]  W. R. Bruce,et al.  Synergistic action of cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on a transplanted murine lymphoma. , 1968, Journal of the National Cancer Institute.

[32]  R. Lukes,et al.  The pathology and nomenclature of Hodgkin's disease. , 1966, Cancer research.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  V. Devita.  The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture , 1981, Cancer.

[35]  R. Abrams,et al.  Amplification of circulating granulocyte-monocyte stem cell numbers following chemotherapy in patients with extensive small cell carcinoma of the lung. , 1981, Cancer research.

[36]  L. Norton,et al.  The treatment of combination chemotherapy‐resistant Hodgkin disease with single‐agent vinblastine , 1978, American journal of hematology.

[37]  D. Cox.  Regression Models and Life-Tables , 1972 .